Last Updated : November 22, 2024
The latest Reimbursement Review reports are posted to this page. Our Reimbursement Reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
For each drug, plasma product, or cell and gene therapy reviewed in the Drug Reimbursement Review process, there is an opportunity for patient groups and clinician groups to provide input and feedback. See Reimbursement Review Open Calls for Input and Feedback.
Brand Name Sort descending | Generic Name | Therapeutic Area | Recommendation Type | Project Status | Date Submission Received | Date Recommendation Issued |
---|---|---|---|---|---|---|
Iluvien | fluocinolone acetonide intravitreal implant | diabetic macular edema | Do not reimburse | Complete | ||
Imbruvica | ibrutinib | Chronic graft versus host disease | Canada’s Drug Agency is unable to make a reimbursement recommendation as the manufacturer has not filed a submission. | Not filed | ||
Imbruvica | ibrutinib | Leukemia | Canada’s Drug Agency is unable to make a reimbursement recommendation as the manufacturer has not filed a submission. | Not filed | ||
Imbruvica | ibrutinib | Chronic lymphocytic leukemia (CLL) | Reimburse with clinical criteria and/or conditions | Complete | ||
Imbruvica | ibrutinib | Leukemia | Canada’s Drug Agency is unable to make a reimbursement recommendation as the manufacturer has not filed a submission. | Not filed | ||
Imbruvica | Ibrutinib | Chronic Lymphocytic Leukemia/ Small Lymphocytic Lymphoma | Reimburse with clinical criteria and/or conditions | Complete | ||
Imbruvica | Ibrutinib | Chronic Lymphocytic Leukemia (previously untreated) | Reimburse with clinical criteria and/or conditions | Complete | ||
Imbruvica | Ibrutinib | Waldenstrom's Macroglobulinemia | Do not reimburse | Complete | ||
Imbruvica | Ibrutinib | Mantle Cell Lymphoma (relapsed/refractory) | Reimburse with clinical criteria and/or conditions | Complete | ||
Imbruvica | ibrutinib | Waldenström’s Macroglobulinemia | Reimburse with clinical criteria and/or conditions | Complete | ||
Imcivree | setmelanotide | Bardet-Biedl syndrome | Reimburse with clinical criteria and/or conditions | Complete | ||
Imdelltra | tarlatamab | Extensive stage small cell lung cancer | Active | |||
Imfinzi | Durvalumab | Unresectable Non-Small Cell Lung Cancer (NSCLC) | Reimburse with clinical criteria and/or conditions | Complete | ||
Imfinzi | durvalumab | Extensive-stage small cell lung cancer | Reimburse with clinical criteria and/or conditions | Complete | ||
Imfinzi | durvalumab | Biliary tract cancer | Reimburse with clinical criteria and/or conditions | Complete | ||
Imfinzi | durvalumab | limited-stage small cell lung cancer (LS-SCLC) | Received | |||
Imfinzi | durvalumab | resectable non-small cell lung cancer (NSCLC) | Suspended | |||
Imfinzi | durvalumab, carboplatin, paclitaxel | Endometrial cancer that is mismatch repair deficient (dMMR) | Active | |||
Imfinzi and Imjudo | durvalumab and tremelimumab | unresectable hepatocellular carcinoma | Reimburse with clinical criteria and/or conditions | Complete | ||
Imfinzi, Imjudo | durvalumab, tremelimumab | Metastatic non-small cell lung cancer (NSCLC) | Active | |||
Imfinzi, Lynparza | durvalumab, olaparib, carboplatin, paclitaxel | Endometrial cancer that is mismatch repair proficient (pMMR) | Active | |||
Imvexxy | estradiol | Dyspareunia | Reimburse with clinical criteria and/or conditions | Complete | ||
Incivek | Telaprevir | Hepatitis C, chronic | List with clinical criteria and/or conditions | Complete | ||
Incivek | Telaprevir | Hepatitis C, chronic | List with criteria/condition | Complete | ||
Incivek | Telaprevir | Hepatitis C, chronic | List with criteria/condition | Complete |